[HTML][HTML] Major depressive disorder: Validated treatments and future challenges

R Karrouri, Z Hammani, R Benjelloun… - World journal of clinical …, 2021 - ncbi.nlm.nih.gov
Depression is a prevalent psychiatric disorder that often leads to poor quality of life and
impaired functioning. Treatment during the acute phase of a major depressive episode aims …

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments

KT Greenway, N Garel, L Jerome… - Expert Review of …, 2020 - Taylor & Francis
Introduction Combinations of psychotherapy with antidepressants are gold-standard
psychiatric treatments. They operate through complex and interactional mechanisms, not …

[HTML][HTML] Psychological and psychopharmacological interventions in psychocardiology

KG Kahl, B Stapel, CU Correll - Frontiers in Psychiatry, 2022 - frontiersin.org
Patients with mental disorders have an increased risk to develop cardiovascular disease
(CVD), and CVD are frequently comorbid with especially adjustment, anxiety and depressive …

Protein-C reactive as biomarker predictor of schizophrenia phases of illness? A systematic review

L Orsolini, F Sarchione, F Vellante… - Current …, 2018 - ingentaconnect.com
Background: Schizophrenia is a complex illness in which genetic, environmental, and
epigenetic components have been implicated. However, recently, psychiatric disorders …

[HTML][HTML] The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: a short-term, randomized, double-blind, exploratory …

BT Baune, LB Sluth, CK Olsen - Journal of affective disorders, 2018 - Elsevier
Abstract Background Major Depressive Disorder (MDD) is a complex disease characterized
by emotional, physical and cognitive symptoms. We explored the efficacy of vortioxetine …

Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes

M Di Nicola, M Pepe, S Montanari, MC Spera… - European …, 2023 - Elsevier
Abstract Major Depressive Episodes (MDE) following COVID-19 are frequent, can have a
characteristic clinical picture, and are associated with immune-inflammatory changes …

New pharmacologic approaches to the treatment of bipolar depression

K Keramatian, T Chakrabarty, A DuBow, G Saraf… - Drugs, 2023 - Springer
Depression is the most commonly experienced mood state over the life span in individuals
with bipolar disorder (BD) and is the primary driver of functional impairment and suicidality in …

What is new about new antidepressants?

SL Dubovsky - Psychotherapy and psychosomatics, 2018 - karger.com
Depressed patients and their physicians naturally expect that each new antidepressant that
reaches the market will represent a conceptual and therapeutic advance over previous …

Molecular and cellular dissection of NMDA receptor subtypes as antidepressant targets

E Lang, AS Mallien, AN Vasilescu, D Hefter… - Neuroscience & …, 2018 - Elsevier
A growing body of evidence supports the idea that drugs targeting the glutamate system may
represent a valuable therapeutic alternative in major depressive disorders (MDD). The rapid …

The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions

M Fornaro, M Solmi, N Veronese… - … Review of Psychiatry, 2017 - Taylor & Francis
Cardio-vascular diseases (CVDs) and CVD-related disorders (including cerebrovascular
diseases; CBVDs) are a major public health concern as they represent the leading cause of …